Arbaclofen extended release - Osmotica Pharmaceutical

Drug Profile

Arbaclofen extended release - Osmotica Pharmaceutical

Alternative Names: Arbaclofen extended release tablets (AERT) - Osmotica Pharmaceutical; Ontinua ER; OS-440

Latest Information Update: 19 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Osmotica Pharmaceutical
  • Class Aminobutyric acids; Gastrokinetics; Muscle relaxants; Small molecules
  • Mechanism of Action GABA B receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Muscle spasticity

Most Recent Events

  • 28 Jan 2018 Osmotica Pharmaceutical initiates a phase III trial for Muscle spasticity (in patients with Multiple sclerosis) in USA (PO) (NCT03290131)
  • 27 Oct 2017 Osmotica Pharmaceutical plans the OS440-3005 phase III long-term safety trial for Muscle spasticity (in patients with Multiple sclerosis) in February 2018 (NCT03319732)
  • 25 Sep 2017 Osmotica Pharmaceutical plans the OS440-3004 phase III trial for Muscle spasticity (in patients with Multiple sclerosis) (NCT03290131)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top